title: [Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].
authors.affiliation: Division of Nephrology & Endocrinology, Department of Medicine, The University of Tokyo Hospital, Japan.
authors.forename: Yumie
authors.initials: Y
authors.lastname: Wada
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Manabu
authors.initials: M
authors.lastname: Taguchi
authors.forename: Seiji
authors.initials: S
authors.lastname: Fukumoto
authors.forename: Toshiro
authors.initials: T
authors.lastname: Fujita
mesh_terms: D000368:Aged; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077605:Ferric Oxide, Saccharated; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D005937:Glucaric Acid; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced*; D008297:Male; D010018:Osteomalacia / Q000139:chemically induced*
chemical_list: C000717427:FGF23 protein, human; D005290:Ferric Compounds; D006397:Hematinics; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid